Board of Directors

Dr. Jutta Heim, Ph.D. worked for more than 20 years at Ciba-Geigy/Novartis (CH and US). At Novartis, she was involved in the successful development and launch of anti-thrombotic and fibrinolytic products. She established Novartis’ molecular genetics department in oncology, became Novartis’ Senior Scientific Expert in Molecular Biology and a member of the Research Management Board. Jutta completed her career at Novartis heading the Novartis Lead Discovery Center with worldwide responsibility. From 2004 to 2009, Jutta served as CSO at Basilea Pharmaceutica Ltd. a Swiss biopharmaceutical company focusing on anti-infectives, inflammation and oncology. From 2009 to 2013, she served as CTO and CSO at Evolva SA, where she led Evolva’s discovery activities and strengthened the development of its technology platform. She received a Ph.D. from the University of Tübingen in 1981 and holds a professorship in Biotechnology at the Biocenter of the University of Basel.
Jutta is a member of the advisory board of ‘‘Stiftung für Wissenschaftliche Forschung Universität Zürich’’, a board member of Evolva SA and chairs the scientific advisory committee of DNDi/GARDP, a not-for-profit organisation on antimicrobial resistance.

Morten Sommer is the founder and co-founder of four biotech companies, including Microlytic founded in 2006 which served over 150 customers, including 9 of the 10 largest pharmaceutical companies in the world. The company was sold in a cross-border transaction in 2015. Morten is also a Professor at the Technical University of Denmark with a lab of 30 PhD's and Post docs working primarily in the field of antibiotic resistance. Morten is the inventor on 10+ issued patents, patent applications and author of scientific papers in journals such as Science and Nature. Dr. Sommer holds a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.

Ole Skov has more than 30 years of experience in management and entrepreneurship. Since 2008, Mr. Skov has been an Independent Investor and recently entered into an investment partnership with the European Investment Fund. Previously Mr. Skov has been a Management Consultant at McKinsey & Co. from 1987-1994 and subsequently became Managing Partner at Accenture Financial Services from 1994-2007. Mr. Skov is an investor and board member in several companies including Adsidius and Clinical-Microbiomics. Mr. Skov holds a degree in Commerce from Copenhagen Business School and an MBA from IMD in Lausanne, Switzerland.

Rasmus Toft-Kehler has been directly and indirectly involved with a number of new ventures including being the co-founder of Clinical-Microbiomics A/S. Prior to his entrepreneurial career, Rasmus worked in M&A (Goldman Sachs and Gudme Raaschou), management consulting (Booz Allen Hamilton) and in a family-owned enterprise which was successfully sold in 2005. Rasmus holds an executive degree in entrepreneurial leadership from Harvard Business School and a degree in finance and business administration from New York University and Copenhagen Business School. Rasmus’ research on serial entrepreneurship has been taught at Harvard Business School and published in leading entrepreneurship journals. In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.

Stig Løkke Pedersen serves as the chairman of the Board of Directors in NGI A/S, SSI Diagnostica A/S, Moksha8 Ltd, Transmedica A/S and Nuevolution AB. He is a member of the Board of Directors in MSI Methylation Sciences Inc, Skybrands A/S, BroenLab A/S and Index Pharmaceuticals AB. Stig Løkke Pedersen is furthermore operating partner in the private equity fund Catacap A/S. Mr. Pedersen served as Executive Vice President of Commercial Operations at H. Lundbeck A/S, heading all business activities in the Group from 2005 to 2011. Mr. Pedersen joined Lundbeck in 1992 and has served as Director of Business Development, Director of Corporate Affairs and Managing Director of Lundbeck's subsidiary in the Netherlands from 1992 to 1998. In 1998, he became Senior Vice President of Corporate Affairs, where he was responsible for the three product deals, transforming Lundbeck into a global player, namely Lexapro/Cipralex (escitalopram), Ebixa (memantine) and Azilect (rasagiline). In 2001, Mr. Pedersen obtained Operations in America, Asia and Africa. In 2003, he was appointed member of Lundbeck’s Board of Management.
Mr. Pedersen worked for Ciba-Geigy 1986-1992 in Denmark, Switzerland and South Africa.

 

Learn more